GlobalData Plc has completed four acquisitions in a week after securing a £340 million funding facility late last year.
The London-headquartered data, analytics and insights giant split into three divisions last June as it completed a £434m private equity deal which saw it hand over a minority 40% stake in its healthcare business to Inflexion.
That valued the healthcare segment at £1.1 billion. The subsequent funding facility included £176.6m for its healthcare business, which has now completed the acquisition of Deallus, a competitive intelligence solutions provider focused on the global life sciences sector.
During its 20 years in business, Deallus – led by CEO Pete Hempshall (pictured) – has built deep sector expertise through supporting clients in key therapy areas, including oncology, neuroscience, vaccines, rare diseases, cell & gene, and immunology.
GlobalData said the deal creates an opportunity for the group to build deeper, more embedded relationships with major brands within the pharmaceutical sector.
The transaction represents the fourth acquisition completed in H2 2024, in addition to the acquisitions of Business Trade Media International, LinkUp and Celent, which completed on 31st December.
“This acquisition further enhances our capabilities in delivering life sciences solutions, allowing us to deliver even more comprehensive insights and services to our clients,” said Mike Danson, CEO of GlobalData Plc.
“Deallus’s deep sector expertise and client-first mindset perfectly align with our mission to empower decision-makers in navigating the complexities of the healthcare landscape. Together, we are poised to drive remarkable growth and deliver exceptional value to our stakeholders.”
‘Growing up in wheelchair drove me to shake up the care business’